Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization

BACKGROUND: Accurate assessment of the human epidermal growth factor receptor 2 (HER2) of invasive breast cancer is essential to treatment decisions since the advent of targeted therapy with the humanized monoclonal antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib. In the litera...

Descripción completa

Detalles Bibliográficos
Autor principal: Vogel, Ulrich F
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923103/
https://www.ncbi.nlm.nih.gov/pubmed/20670419
http://dx.doi.org/10.1186/1746-1596-5-50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923103/
https://www.ncbi.nlm.nih.gov/pubmed/20670419
http://dx.doi.org/10.1186/1746-1596-5-50

Ejemplares similares